FDA Approves Lilly’s Retevmo for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
Eli Lilly and Company (NYSE: LLY) today announced the U.S.
$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 10.04% on an annualized basis producing an average annual return of 20.46%. Currently, Eli Lilly has a market capitalization of $290.05 billion.
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
As part of President Joe Biden’s executive order to beef up U.S. biomanufacturing, the U.S. Department of Health and Human…
Biden Administration Pushes ‘Cancer Moonshot’ Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."
The President underscored his goal to cut the cancer death rate in the U.S. by at least 50% over the next 25 years.
Eli Lilly Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:LLY) we detected 15 strange trades.
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Key Takeaways:
The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million
Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the company has still not yet filed an application to market the product
By Molly Wen
Tesla Fame’s Robot-Run ETF Sold Its Entire Apple Stake In August — Here’s What It Bought
A large-cap-momentum-focused, AI-powered exchange-traded fund (ETF) sponsored by Qraft Technologies shed its entire Apple Inc. (NASDAQ: AAPL) stake in August, according to an update on monthly holdings issued by the South Korea-based company.
Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for…
Eli Lilly Says Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly’s Phase 3 Monotherapy Atopic Dermatitis Trials
New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity
Results suggest less
Lilly Announced Details of Presentations at ESMO Congress 2022
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, to be held September 9-13, 2022.
Presentation Highlights
Verzenio (abemaciclib)